July 25, 2023 03:09 PM EDT
Pharma
FDA+

Boehringer In­gel­heim, Eli Lil­ly's Jar­diance nabs ap­proval in Eu­rope for chron­ic kid­ney dis­ease

Lia DeGroot

Boehringer In­gel­heim and Eli Lil­ly said Jar­diance re­ceived ap­proval in Eu­rope as a treat­ment for chron­ic kid­ney dis­ease in adults, with the FDA’s de­ci­sion on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times